A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation - Wikidata - wikimedia - TriplyDB

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

http://www.wikidata.org/entity/Q35195588

about

Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patients Interaction of TAFII105 with selected p65/RelA dimers is associated with activation of subset of NF-kappa B genes Emerging roles for the non-canonical IKKs in cancer Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription The NF-κB Pathway and Cancer Stem Cells Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-κB signaling Role of ABL family kinases in cancer: from leukaemia to solid tumours Inactivation of NF-kappaB-dependent cell survival, a novel mechanism for the proapoptotic function of c-Abl Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis Gene set analysis exploiting the topology of a pathway.The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.The unique N-terminus of R-ras is required for Rac activation and precise regulation of cell migration.Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway.Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion.Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation.Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.Jak2 is involved in c-Myc induction by Bcr-Abl.NF-kappaB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression.Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.Studying the pathogenesis of BCR-ABL+ leukemia in mice.NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity.Endoplasmic reticulum stress activates telomerase.NF-κB addiction and its role in cancer: 'one size does not fit all'.NF-kappaB and cancer: how intimate is this relationship Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway BCR/ABL inhibition by an escort/phosphatase fusion protein Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.MUC1 induced by Epstein-Barr virus latent membrane protein 1 causes dissociation of the cell-matrix interaction and cellular invasiveness via STAT signaling.Considerations for targeting malignant stem cells in leukemia.Novel therapies for patients with chronic myeloid leukemia.MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825 ROCK I-mediated activation of NF-kappaB by RhoB

P2860

Q22254246-4978FB48-2A0F-4A92-99F9-D006CF1F70BD Q22254261-150CF190-6261-4C16-94E5-3A14E800AF06 Q24305225-E6E2A353-50B1-46A5-9BA2-E85850D7B3B9 Q24658292-4F1F8C30-A65C-4F2B-B47B-6A385565F9BD Q24683168-70AB2AC6-9676-4142-8B47-D04980C03902 Q26750605-521F4F2E-CC87-4726-BC78-2AB6C5AD27B9 Q28383134-6B39E3EA-6B56-4D37-8A2F-F85FFB5D83FA Q28387183-79B99673-8D80-486C-B13A-4B9D9B036432 Q28396643-B60D220A-2CBF-4512-87C7-5EB02758E38B Q28588928-ECFC237E-658B-4C86-B2B7-BCDCC339614E Q30168802-3213BAEB-62FF-4F81-A459-93D2F0576151 Q30175784-000AC13B-33BB-4DBC-A148-FF7346649385 Q30988680-CF80ACA4-6BA8-4813-B774-C5EE2766AFC9 Q33226589-87C9E6F4-AD7A-4200-8A93-20C6F77F7386 Q33663180-DB463966-6A77-46D7-A1AA-1752048584D9 Q33747277-A88DFCDE-B34D-42EF-A3C9-6574ABD9FC14 Q33768553-02022F92-8991-41CC-AB35-365481BEEF12 Q33872322-2FF80455-B637-4D81-A564-607E5119C62D Q33908547-0AA49F43-A249-407D-ABD5-0FF86BBB2297 Q33944952-B721B061-5B61-4040-A90F-B6B2A73FA5F7 Q33959017-3475E605-BED8-427D-908A-C20E45EB0E66 Q33960372-CA772361-E1A6-47C9-A31B-14AD674F19AD Q34032219-3BDE04C6-F75C-4D6B-8BC9-0AAA9223E32E Q34131747-1E231AF4-DE9A-494A-928B-5F7B646E8E23 Q34153616-7A54DC84-0962-41B7-BF05-C6E8CC823B98 Q34283905-A4B642FF-AFF3-424D-AFBB-F75B87798C89 Q34819481-9C9859C3-4325-47BB-ACA9-2B0D9763354C Q35022543-FA180D91-8C4E-4D43-B70F-218FB245130D Q35071293-21AD4764-5816-42DF-952A-CBC9FB28A627 Q35080451-9544344F-268D-439A-B285-99C13AAC2EAE Q35120893-1E453BCE-5A3B-40AA-9494-59D77B98EB48 Q35143597-9872751F-1542-4A44-9BCF-8219350C3B71 Q35200289-FABD1ECC-EAC1-4C95-8728-F0358BDCEA20 Q35410948-885BF4B8-C6D7-40DA-AE19-1D4CBEE112E6 Q35510549-5A8C5B4A-F6A6-4303-93C9-69B82BC1570E Q35635449-5803C580-1C52-45F8-BFB8-5D31F30A40A8 Q35692619-95923934-018E-43E3-ACD7-CE1AD1785DBB Q35728742-E939269E-D54F-4BAC-A076-9D1479DC3F9F Q35804449-7BF85396-3F3E-4FDC-A7AB-A5347188DF45 Q36156141-3C48D794-4302-496D-914F-B70454487B98

P2860

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

http://www.wikidata.org/entity/Q35195588

description

1998 nî lūn-bûn

@nan

1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

@ast

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

@en

type

label

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

@ast

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

@en

prefLabel

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

@ast

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

@en

P1433

Q35195588-E0E3935E-F9AE-40E2-80FC-907E6E8BA2A0

P1476

Q35195588-202651E5-FA36-4564-9823-6B7F531C4BC3

P2093

Q35195588-522FA952-A0E8-47A2-A27B-DD443A0F157D

Q35195588-6732261B-866A-4280-A8F2-4D378944B67B

Q35195588-940E3323-BF78-48A7-92A9-31D0B51C22F4

Q35195588-AE858F84-AE9C-4588-A811-51B96B5E24F6

Q35195588-D40A88A0-CB21-412B-9B08-44B496025D98

P2860

Q35195588-0B146EA4-F575-44E3-B55D-9C4AE761989C

Q35195588-0B6E0CEC-689E-46D9-8D1C-5BBEBE84D01F

Q35195588-0BC8F55A-5FC0-4057-ABFD-DEC7FA4CFC01

Q35195588-0E0CA6D4-25C9-40D1-B724-55D0940726AB

Q35195588-108D9BAD-C855-4E4F-8171-AA81CA5FFA41

Q35195588-14C8B714-E863-47FE-B95C-D6E7AD3CFA01

Q35195588-14F78C46-BD7A-461B-82F9-E9B091E5185B

Q35195588-15EF4A6D-9084-4BC9-AB57-50E685AAAE31

Q35195588-1AB630DC-B190-426A-83EA-0DD2A7667365

Q35195588-1D00E1A1-DB6F-4C9D-97CD-45FD27FF8A18

P304

Q35195588-AF03CE2E-3320-4525-9F16-FC79EB21F067

P31

Q35195588-861DD177-AB26-4A44-B1E2-267FAC2EB4B4

P356

Q35195588-7CB87A41-B7B2-4A06-937C-6BCE49D6B0BE

P433

Q35195588-A10BABCE-79E4-446D-89E4-9E49FEE5918E

P478

Q35195588-5A71B1A2-AF78-479F-BC13-E3C1B178F58B

P577

Q35195588-637ABC08-598F-483F-9752-9159E1352838

P5875

Q35195588-A72783CB-E2E2-4DED-B6EC-ED5B608FEE92

P698

Q35195588-28137903-2535-4894-AAF9-C49CA72EE148

P921

Q35195588-37EDC2F0-6998-4EF9-B12B-EF7A180DAD0C

P932

Q35195588-8752BD47-2875-490C-B2A2-056589AEF137

P356

P1433

Genes & Development

P1476

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

@en

P2093

A M Pendergast

http://www.w3.org/2001/XMLSchema#string

A S Baldwin

http://www.w3.org/2001/XMLSchema#string

D Cortez

http://www.w3.org/2001/XMLSchema#string

G W Reuther

http://www.w3.org/2001/XMLSchema#string

J Y Reuther

http://www.w3.org/2001/XMLSchema#string

P2860

I kappa B: a specific inhibitor of the NF-kappa B transcription factor

I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding

Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65

The NF-kappa B and I kappa B proteins: new discoveries and insights

B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50

Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation

NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway

A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB

Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus

Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli

P304

968-981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1101/GAD.12.7.968

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

1998-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51323966

http://www.w3.org/2001/XMLSchema#string

P698

9531535

http://www.w3.org/2001/XMLSchema#string

P921

P932

316671

http://www.w3.org/2001/XMLSchema#string